A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SSRI / serotonin selective reuptake inhibitor

[Related PubMed/MEDLINE]
Total Number of Papers: 101
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SSRI  (>> Co-occurring Abbreviation)
Long Form:   serotonin selective reuptake inhibitor
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer's disease mice. AD, NPS
2020 Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. CBT, CKD
2019 Co-Morbid Erectile Dysfunction (ED) and Antidepressant Treatment in a Patient - A Management Challenge? AD, ED, PDE5i, SD, SNRI, TCA
2019 In Utero Exposure to Citalopram Mitigates Maternal Stress Effects on Fetal Brain Development. CIT
2019 Neonatal infant EEG bursts are altered by prenatal maternal depression and serotonin selective reuptake inhibitor use. CNS
2018 Serotonin transporter inhibition during neonatal period induces sex-dependent effects on mitochondrial bioenergetics in the rat brainstem. SERTs
2018 Somato-Dendritic Regulation of Raphe Serotonin Neurons; A Key to Antidepressant Action. SERT
2016 Antidepressants for treatment of depression in primary care: a systematic review and meta-analysis. CCDAN, NNT, RR, SNRI, TCA
2016 Examining Endothelial Function and Platelet Reactivity in Patients with Depression before and after SSRI Therapy. CVD, MDD
10  2016 Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression. iSPOT-D, SNRI
11  2015 A Case of SSRI Induced Irreversible Parkinsonism. ---
12  2014 Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice. ---
13  2014 The human ether-a'-go-go related gene (hERG) K+ channel blockade by the investigative selective-serotonin reuptake inhibitor CONA-437: limited dependence on S6 aromatic residues. hERG, hERG, WT
14  2014 [Pharmacogenetics and anxiety disorders: analysis of recent findings]. ---
15  2013 Escitalopram for antipsychotic nonresponsive visual hallucinosis: eight patients suffering from Charles Bonnet syndrome. CBS, CGI
16  2013 Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task. ADHD, SNRI, SNRI
17  2013 Neurochemical substrates of MDMA reward: effects of the inhibition of serotonin reuptake on the acquisition and reinstatement of MDMA-induced CPP. CPP, MDMA
18  2013 Sertraline and mirtazapine as geriatric antidepressants. NaSSA, NICE
19  2013 The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? MDD
20  2012 5-HT(2B) receptors are required for serotonin-selective antidepressant actions. ---
21  2012 Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. CI, OR
22  2012 Differential effects of fluoxetine and venlafaxine on memory recognition: possible mechanisms of action. AMPA, NOS1, SERT, SNRI
23  2012 Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. CBT
24  2011 5-HT(1A)-receptor over-expressing mice: genotype and sex dependent responses to antidepressants in the forced swim-test. FST, OE, WT
25  2011 Antidepressants elevate GDNF expression and release from C₆ glioma cells in a beta-arrestin1-dependent, CREB interactive pathway. ADs, GDNF, NSRI
26  2011 Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. MADRS, MDD
27  2011 P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. ECT, MADRS, MDD, P2RX7
28  2010 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'. cPLA2, FACS, RT-PCR, SERT
29  2010 A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. ---
30  2010 A pilot study to evaluate a community pharmacy-based monitoring system to identify adverse drug reactions associated with paediatric medicines use. ADHD, ADRs
31  2010 Does prestroke depression impact poststroke depression and treatment? BSD, CI, OR, PSD
32  2010 Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. SERT, SERTPR
33  2010 Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population. MDD
34  2010 Reduced platelet G protein-coupled receptor kinase 2 in major depressive disorder: antidepressant treatment-induced upregulation of GRK2 protein discriminates between responder and non-responder patients. GRKs, MDD, SNRI
35  2010 Understanding changes in uptake and release of serotonin from gastrointestinal tissue using a novel electroanalytical approach. GI
36  2010 Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. BDNF, ECT, MADRS, MDD, VEGF
37  2009 Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. DA, DLFC, MB, mPFC, NAc
38  2009 Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation. EGF
39  2009 Effects of olanzapine, fluoxetine and olanzapine/fluoxetine on creatine kinase activity in rat brain. CK
40  2009 Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. BDNF, EPM, FST, OF, vHi
41  2009 Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. ---
42  2008 In vitro serotonergic activity of black cohosh and identification of N(omega)-methylserotonin as a potential active constituent. ---
43  2007 Citalopram to treat depression in pediatric oncology. CSM
44  2007 Serotonin-selective reuptake inhibitor-induced enuresis in three pediatric cases. ---
45  2007 The role of phosphodiesterase type 5 inhibitors in the management of premature ejaculation: a critical analysis of basic science and clinical data. IELT, PDE5-Is, PE
46  2007 [Differences in management of depression in Spain from psychiatric and primary care physician point of view]. GP, TCA
47  2006 A comparison of the effects of citalopram and moclobemide on resting brain perfusion in social anxiety disorder. rCBF, RIMA, SAD, SPECT
48  2006 Ghrelin concentrations and cardiac vagal tone are decreased after pharmacologic and cognitive-behavioral treatment in patients with bulimia nervosa. BMI, BN, POMS
49  2006 Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. CGI-S, FET, GAD, HAMA-A
50  2006 Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report. SIADH
51  2006 The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. ---
52  2006 [Neonatal treatment effect with selective inhibitor of 5-HT recapture on [corrected] the cranium-encephalic anatomic development]. ---
53  2006 [Neuropsychiatric symptoms related to interferon alpha]. HPA
54  2005 Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone. 5-HT, 8-OH-DPAT
55  2005 Pindolol is a potent scavenger of reactive nitrogen species. AD
56  2005 The response to sertraline in men with chronic pelvic pain syndrome. CPPS, HAD, PSex, PSS
57  2004 Chronic fluoxetine suppresses circulating estrogen and the enhanced spatial learning of estrogen-treated ovariectomized rats. ---
58  2004 Clomipramine, fluoxetine and CYP2D6 metabolic capacity in depressed patients. MR
59  2004 Depressing research. ---
60  2004 [Comparison of two assessment tools of antidepressant side-effects: UKU scale versus spontaneous notification]. NaSSA, SN, SNRI
61  2003 Electrocardiographic dose-dependent changes in prophylactic doses of dosulepine, lithium and citalopram. ECG, Li, TCA, VCG
62  2003 New drug development for post-traumatic stress disorder. PTSD
63  2003 Orexigenic/anorexigenic signals in bulimia nervosa. AN, BN, ED
64  2003 The combination of olanzapine and fluoxetine in mood disorders. ---
65  2003 [Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors]. CGI, HDRS
66  2002 Relief of serotonin selective reuptake inhibitor induced sexual dysfunction with low-dose mianserin in patients with traumatic brain injury. ---
67  2001 Examining the Saskatchewan health drug database for antidepressant use: the case of fluoxetine. ---
68  2000 Effects of chronic fluoxetine treatment in the presence and absence of (+/-)pindolol: a microdialysis study. ---
69  2000 Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. fEPSP, LTP, rECS
70  2000 The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol. ---
71  2000 Worsening of Parkinson's disease by citalopram. PD
72  1999 A pilot study of mirtazapine in post-traumatic stress disorder. PTSD
73  1999 Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? ---
74  1999 Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. MAOI, TCA
75  1999 Effects of venlafaxine on extracellular concentrations of 5-HT and noradrenaline in the rat frontal cortex: augmentation via 5-HT1A receptor antagonism. AD, DRN, NA, SNRI
76  1999 Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. BARS, EPS, OC, SAS, Y-BOCS
77  1999 Inositol addition does not improve depression in SSRI treatment failures. ---
78  1999 Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor. mCPP, OCD, SPECT
79  1999 Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: reappraisal of interindividual variability factors. HPLC
80  1998 Antidepressant response in late-life depression. ---
81  1998 Antidepressants inhibit the glucocorticoid stimulation of thyrotropin releasing hormone expression in cultured hypothalamic neurons. DESI, FLUO, IMIP, RIA, SERT, TCA, TRH
82  1998 Differential pharmacology of newer antidepressants. ---
83  1998 Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. ---
84  1998 Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. ---
85  1997 Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. TCA
86  1997 Cost-effectiveness of antidepressant treatment reassessed. TCA
87  1997 Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. HAM-D, PGI
88  1996 Does thyroid hormone have a role as adjunctive therapy in depression? TCA
89  1996 Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients. OC
90  1996 Rational polypharmacy in the bipolar affective disorders. MAOI
91  1996 Response to an open trial of a second SSRI in major depression. ---
92  1996 Serotonin dysfunction disorders: a behavioral neurochemistry perspective. ---
93  1996 Serotonin syndrome and fluvoxamine: a case study. ---
94  1996 The antinociceptive effect of fluvoxamine. ---
95  1996 Therapeutic dose range of nefazodone in the treatment of major depression. ---
96  1996 Tolerability and safety: essentials in antidepressant pharmacotherapy. TCAs
97  1995 Are patients who are intolerant to one serotonin selective reuptake inhibitor intolerant to another? ---
98  1995 Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. ---
99  1994 Combined SSRI-moclobemide treatment of psychiatric illness. ---
100  1994 Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. 2-OH-DMI, DES, DMI, FLU, NOR, SERT